(89 days)
Not Found
No
The document describes a synthetic bone void filler and does not mention any AI or ML components or functions.
Yes
InQu is a bone void filler intended to aid in the healing process of bone injuries by providing a scaffold for bone growth. This fulfills the definition of a therapeutic device as it treats a condition.
No
Explanation: The device is described as a resorbable bone void filler and bone graft substitute, intended to fill bony gaps or voids and be replaced by bone during healing. Its function is to facilitate the healing process rather than to identify or diagnose a medical condition.
No
The device description clearly states it is a "sterile, granular, synthetic bone void filler composed of poly (D,L-lactide-co-glycolide) and hyaluronic acid," which are physical materials, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that InQu is a "resorbable bone void filler" and "bone graft substitute" used to fill bony gaps or voids in the skeletal system. This is a therapeutic and structural function, not a diagnostic one.
- Device Description: The description details the composition and function of the material as a paste that resorbs and is replaced by bone. This is consistent with a medical device used for tissue repair and regeneration, not for analyzing samples from the body to diagnose a condition.
- Lack of Diagnostic Elements: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting biomarkers, or providing diagnostic information about a patient's health status.
IVD devices are specifically designed to perform tests on samples taken from the human body to provide information for the diagnosis, monitoring, or treatment of diseases or conditions. InQu's function is to physically fill and support bone healing.
N/A
Intended Use / Indications for Use
InQu is a resorbable bone void filler intended to fill bony gaps or voids that are not intrinsic to the stability of the bony structure. InQu is intended for use as a bone graft substitute in the skeletal system (extremities and pelvis). InQu is indicated for use as a bone graft extender in the spine when combined with bone autograft. These defects may be surgically created osseous defects, or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.
Product codes
MQV
Device Description
InQu® Paste Mix is intended for single patient use only. The device is a sterile, granular, synthetic bone void filler composed of poly (D,L-lactide-co-glycolide) and hyaluronic acid. InQu is combined with a fluid (e.g. saline or blood) to form a paste, which is easily placed into bony voids. It resorbs and is replaced with bone during the healing process.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system (extremities and pelvis), spine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
ISTO performed a study comparing the dissolution rate and characteristics of the smaller granule size in the Paste Mix to the granules in the predicate devices. The results show the two forms do not have significant differences.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
K1118358
Submitter:
ISTO Technologies, Inc.
InQu® Paste Mix
Traditional 510(k)
Section 5.0
510(k) Summary
SEP 2 6 2011
| Submitter Name: | ISTO Technologies, Inc. |
|---|---|
| Submitter Address: | 1155 Olivette Executive Parkway, Suite 200 |
| St. Louis, Missouri 63132 | |
| Contact Person: | Penny White |
| Vice President, Regulatory Affairs and Quality Assurance | |
| Direct Number: | 314-262-8007 |
| Company Main Number: | 314-995-6049 |
| Fax Number: | 314-995-6025 |
| Date Prepared: | June 27, 2011 |
| Device Trade Name: | InQu ® Paste Mix |
| Device Common Name: | Resorbable bone void filler |
| Classification Name: | Filler, bone void, calcium salt compound |
| Classification Number: | 21 CFR 888.3045 |
| Product Code: | MQV |
| Predicate Devices: | InQu ® ISTO Technologies, Inc., K063359 |
| InQu ® ISTO Technologies, Inc., K071428 | |
| Statement of | |
| Intended Use: | InQu ® is a resorbable bone void filler intended to fill bony gaps or |
| voids that are not intrinsic to the stability of the bony structure. InQu ® | |
| is intended for use as a bone graft substitute in the skeletal system | |
| (extremities and pelvis). InQu ® is indicated for use as a bone graft | |
| extender in the spine when combined with bone autograft. These | |
| defects may be surgically created osseous defects, or osseous | |
| defects created from traumatic injury to the bone. The product | |
| provides a bone void filler that resorbs and is replaced with bone | |
| during the healing process. | |
| Device Description, | |
| Summary of | |
| Technological | |
| Characteristics | InQu ® Paste Mix is intended for single patient use only. The device is |
| a sterile, granular, synthetic bone void filler composed of poly (D,L- | |
| lactide-co-glycolide) and hyaluronic acid. InQu is combined with a | |
| fluid (e.g. saline or blood) to form a paste, which is easily placed into | |
| bony voids. It resorbs and is replaced with bone during the healing | |
| process. | |
| Device Testing | ISTO performed a study comparing the dissolution rate and |
| characteristics of the smaller granule size in the Paste Mix to the | |
| granules in the predicate devices. The results show the two forms do | |
| not have significant differences. | |
| Comparison to the | |
| Predicate Device | The new device is substantially equivalent to the predicate devices in |
| terms of intended use, material composition and technological | |
| characteristics, as shown in the above testing. |
·
រឿ
ﯿﻦ
1
Image /page/1/Picture/1 description: The image shows a logo with a circular border containing text. Inside the circle is a stylized image of an eagle or bird in flight, represented by three curved lines that suggest movement and wings. The text around the border appears to be part of an organization's name, possibly related to health or human services.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20903-0002
ISTO Technologies. Incorporated % Ms. Penny White Vice President, Regulatory Affairs and Quality Assurance 1155 Olivette Executive Parkway, Suite 200 Saint Louis, Missouri 63132
Re: K111838
SEP. 26, 2011
Trade/Device Name: InQui® Paste Mix Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: II Product Code: MQV Dated: August 16. 2011 Received: August 17. 2011
Dear Ms. White:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or 10 devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
2
Page 2 - Ms. Penny White
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.
ff you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
Eunel Keith
Sr Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
| 510(k) Number (if known): | KII1438 |
|---|---|
| --------------------------- | --------- |
Device Name:
InQu® Paste Mix
Indications for Use:
InQue is a resorbable bone void filler intended to fill bony gaps or voids that are not intrinsic to the stability of the bony structure. InQue is intended for use as a bone graft substitute in the skeletal system (extremities and pelvis). InQue is indicated for use as a bone graft extender in the spine when combined with bone autograft. These defects may be surgically created osseous defects, or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH. Office of Device Evaluation (ODE)
signature
(Division S Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K111838